{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T03:30:11Z","timestamp":1786505411816,"version":"build-2736575974"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"DOI":"10.1007\/s12029-026-01565-0","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T03:06:31Z","timestamp":1786503991000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Third-Line Treatment Timing After Second-Line Discontinuation in Advanced Pancreatic Cancer: A 30-Day Landmark Analysis"],"prefix":"10.1007","volume":"57","author":[{"given":"Kohei","family":"Nagata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4920-5130","authenticated-orcid":false,"given":"Shinya","family":"Kajiura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miho","family":"Sakumura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yurika","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iori","family":"Motoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Banri","family":"Ogino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Kawanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiki","family":"Entani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiko","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Yasuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,12]]},"reference":[{"issue":"4","key":"1565_CR1","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s10147-023-02317-x","volume":"28","author":"T Okusaka","year":"2023","unstructured":"Okusaka T, Nakamura M, Yoshida M, Kitano M, Ito Y, Mizuno N, et al. Clinical practice guidelines for pancreatic cancer 2022 from the Japan Pancreas Society: a synopsis. Int J Clin Oncol. 2023;28(4):493\u2013511. https:\/\/doi.org\/10.1007\/s10147-023-02317-x.","journal-title":"Int J Clin Oncol"},{"issue":"11","key":"1565_CR2","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/j.annonc.2023.08.009","volume":"34","author":"T Conroy","year":"2023","unstructured":"Conroy T, Pfeiffer P, Vilgrain V, Lamarca A, Seufferlein T, O\u2019Reilly EM, et al. Pancreatic cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(11):987\u20131002. https:\/\/doi.org\/10.1016\/j.annonc.2023.08.009.","journal-title":"Ann Oncol"},{"issue":"19","key":"1565_CR3","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M, Bouch\u00e9 O, Guimbaud R, B\u00e9couarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817\u201325. https:\/\/doi.org\/10.1056\/NEJMoa1011923.","journal-title":"N Engl J Med"},{"issue":"18","key":"1565_CR4","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691\u2013703. https:\/\/doi.org\/10.1056\/NEJMoa1304369.","journal-title":"N Engl J Med"},{"issue":"10018","key":"1565_CR5","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/s0140-6736(15)00986-1","volume":"387","author":"A Wang-Gillam","year":"2016","unstructured":"Wang-Gillam A, Li CP, Bodoky G, Dean A, Shan YS, Jameson G, et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet. 2016;387(10018):545\u201357. https:\/\/doi.org\/10.1016\/s0140-6736(15)00986-1.","journal-title":"Lancet"},{"issue":"11","key":"1565_CR6","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1016\/j.ejca.2011.04.011","volume":"47","author":"U Pelzer","year":"2011","unstructured":"Pelzer U, Schwaner I, Stieler J, Adler M, Seraphin J, D\u00f6rken B, et al. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. Eur J Cancer. 2011;47(11):1676\u201381. https:\/\/doi.org\/10.1016\/j.ejca.2011.04.011.","journal-title":"Eur J Cancer"},{"issue":"4","key":"1565_CR7","doi-asserted-by":"publisher","first-page":"104528","DOI":"10.1016\/j.esmoop.2025.104528","volume":"10","author":"T Conroy","year":"2025","unstructured":"Conroy T, Ducreux M. ESMO clinical practice guideline express update on the management of metastatic pancreatic cancer. ESMO Open. 2025;10(4):104528. https:\/\/doi.org\/10.1016\/j.esmoop.2025.104528.","journal-title":"ESMO Open"},{"issue":"2","key":"1565_CR8","doi-asserted-by":"publisher","first-page":"362","DOI":"10.21037\/hbsn-24-37","volume":"13","author":"C Springfeld","year":"2024","unstructured":"Springfeld C, Bailey P, B\u00fcchler MW, Neoptolemos JP. ESMO 2023 pancreatic cancer guidelines signal stepwise progress. Hepatobiliary Surg Nutr. 2024;13(2):362\u20135. https:\/\/doi.org\/10.21037\/hbsn-24-37.","journal-title":"Hepatobiliary Surg Nutr"},{"issue":"4","key":"1565_CR9","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1093\/aje\/kwm324","volume":"167","author":"S Suissa","year":"2008","unstructured":"Suissa S. Immortal time bias in pharmaco-epidemiology. Am J Epidemiol. 2008;167(4):492\u20139. https:\/\/doi.org\/10.1093\/aje\/kwm324.","journal-title":"Am J Epidemiol"},{"issue":"23","key":"1565_CR10","doi-asserted-by":"publisher","first-page":"2963","DOI":"10.1200\/jco.2013.49.5283","volume":"31","author":"A Giobbie-Hurder","year":"2013","unstructured":"Giobbie-Hurder A, Gelber RD, Regan MM. Challenges of guarantee-time bias. J Clin Oncol. 2013;31(23):2963\u20139. https:\/\/doi.org\/10.1200\/jco.2013.49.5283.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1565_CR11","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1097\/ju.0000000000003459","volume":"209","author":"EC Zabor","year":"2023","unstructured":"Zabor EC, Assel M. On the need for landmark analysis or time-dependent covariates. J Urol. 2023;209(6):1060\u20132. https:\/\/doi.org\/10.1097\/ju.0000000000003459.","journal-title":"J Urol"},{"issue":"1","key":"1565_CR12","doi-asserted-by":"publisher","first-page":"300","DOI":"10.21037\/tlcr-24-1002","volume":"14","author":"KM Tsuruda","year":"2025","unstructured":"Tsuruda KM, Hektoen HH, Costa DR, Andreassen BK. Immortal time bias in survival outcomes when comparing treatment with chemotherapy versus immunochemotherapy for non-small cell lung cancer. Translational Lung Cancer Res. 2025;14(1):300\u20132.","journal-title":"Translational Lung Cancer Res"},{"issue":"8","key":"1565_CR13","doi-asserted-by":"publisher","first-page":"573","DOI":"10.7326\/0003-4819-147-8-200710160-00010","volume":"147","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med. 2007;147(8):573\u20137. https:\/\/doi.org\/10.7326\/0003-4819-147-8-200710160-00010.","journal-title":"Ann Intern Med"},{"issue":"3","key":"1565_CR14","doi-asserted-by":"publisher","first-page":"155932582094206","DOI":"10.1177\/1559325820942065","volume":"18","author":"W Fu","year":"2020","unstructured":"Fu W, Wang K, Yan S, Wang X, Tang B, Chang J, et al. Prognostic significance of the modified glasgow prognostic score in patients with pancreatic cancer: a meta-analysis. Dose Response. 2020;18(3):1559325820942065. https:\/\/doi.org\/10.1177\/1559325820942065.","journal-title":"Dose Response"},{"issue":"6","key":"1565_CR15","doi-asserted-by":"publisher","first-page":"4430","DOI":"10.21037\/apm.2019.09.06","volume":"9","author":"PYP Ho","year":"2019","unstructured":"Ho PYP, Lee HFV. Factors correlating with shorter survival after treatment: aiding oncologists to choose who (not) to receive palliative systemic therapy. Annals Palliat Med. 2019;9(6):4430\u201345.","journal-title":"Annals Palliat Med"},{"issue":"7\u20138","key":"1565_CR16","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1111\/ans.18906","volume":"94","author":"B Law","year":"2024","unstructured":"Law B, Windsor J, Connor S, Koea J, Srinivasa S. Best supportive care in advanced pancreas cancer: a systematic review to define a patient-care bundle. ANZ J Surg. 2024;94(7\u20138):1254\u20139. https:\/\/doi.org\/10.1111\/ans.18906.","journal-title":"ANZ J Surg"},{"issue":"5","key":"1565_CR17","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.21037\/jgo-23-488","volume":"14","author":"A Talbot","year":"2023","unstructured":"Talbot A, Talbot T, Shaughnessy E, Glass A, Das A, Watanabe Y, et al. Overall survival and treatment modalities in pancreatic adenocarcinoma: a retrospective analysis of a single centre in Western Australia. J Gastrointest Oncol. 2023;14(5):2221\u20138.","journal-title":"J Gastrointest Oncol"},{"issue":"6","key":"1565_CR18","doi-asserted-by":"publisher","first-page":"oyaf125","DOI":"10.1093\/oncolo\/oyaf125","volume":"30","author":"C Evrard","year":"2025","unstructured":"Evrard C, Pelras A, Rivet S, Bachet J-B, Dubreuil O, Pointet A-L, et al. Predictive and prognostic factors of efficacy of third-line chemotherapy in patients with unresectable pancreatic cancer: a cohort-based study. Oncologist. 2025;30(6):oyaf125. https:\/\/doi.org\/10.1093\/oncolo\/oyaf125.","journal-title":"Oncologist"},{"key":"1565_CR19","doi-asserted-by":"publisher","first-page":"1626689","DOI":"10.3389\/fonc.2025.1626689","volume":"15","author":"K Miwa","year":"2025","unstructured":"Miwa K, Kawasaki R, Shimokawa M, Otsuka T, Tanaka T, Fukahori M, et al. Efficacy of third-line chemotherapy following nanoliposomal irinotecan combined with fluorouracil and folinic acid as second-line treatment for unresectable pancreatic cancer. Front Oncol. 2025;15:1626689. https:\/\/doi.org\/10.3389\/fonc.2025.1626689.","journal-title":"Front Oncol"},{"issue":"2","key":"1565_CR20","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s10555-025-10260-8","volume":"44","author":"JJ Adashek","year":"2025","unstructured":"Adashek JJ, Moran JA, Le DT, Kurzrock R. Lessons learned from a decade of immune checkpoint inhibition: The good, the bad, and the ugly. Cancer Metastasis Rev. 2025;44(2):43. https:\/\/doi.org\/10.1007\/s10555-025-10260-8.","journal-title":"Cancer Metastasis Rev"},{"key":"1565_CR21","doi-asserted-by":"publisher","first-page":"1251258","DOI":"10.3389\/fonc.2023.1251258","volume":"13","author":"HR Lu","year":"2023","unstructured":"Lu HR, Zhu PF, Deng YY, Chen ZL, Yang L. Third-line treatment options in metastatic pancreatic cancer patients: a real-world study. Front Oncol. 2023;13:1251258. https:\/\/doi.org\/10.3389\/fonc.2023.1251258.","journal-title":"Front Oncol"},{"key":"1565_CR22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2605555","author":"EM O\u2019Reilly","year":"2026","unstructured":"O\u2019Reilly EM, Wainberg ZA, Hendifar AE, Borad MJ, Pietrantonio F, Pant S, et al. Daraxonrasib or chemotherapy in previously treated metastatic pancreatic cancer. N Engl J Med. 2026. https:\/\/doi.org\/10.1056\/NEJMoa2605555.","journal-title":"N Engl J Med"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01565-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-026-01565-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01565-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T03:06:35Z","timestamp":1786503995000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-026-01565-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,12]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1565"],"URL":"https:\/\/doi.org\/10.1007\/s12029-026-01565-0","relation":{},"ISSN":["1941-6636"],"issn-type":[{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,12]]},"assertion":[{"value":"4 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki. The protocol was approved by the Institutional Review Board of Toyama University Hospital (approval no. R2025155).","order":1,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. Informed consent was waived by the Institutional Review Board under an opt-out procedure.","order":2,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable, as no identifiable personal data are included in this manuscript.","order":3,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":5,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During the preparation of this work, the authors used ChatGPT (OpenAI) for language editing and readability support. After using this tool, the authors reviewed and edited the content as needed and take full responsibility for the content of the manuscript.","order":6,"name":"Ethics","label":"Generative AI and AI-Assisted Technologies in the Writing Process","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"182"}}